{"id":"once-daily-immunosuppression-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Bone marrow suppression"}]},"_chembl":{"chemblId":"CHEMBL1189432","moleculeType":"Small molecule","molecularWeight":"337.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This represents a dosing innovation rather than a novel molecular mechanism, designed to improve patient adherence and convenience in transplant or autoimmune disease management. The regimen typically combines or reformulates existing immunosuppressive drugs (such as calcineurin inhibitors, antiproliferatives, or corticosteroids) to achieve once-daily dosing while maintaining adequate drug exposure and efficacy.","oneSentence":"A once-daily immunosuppressive regimen that reduces the frequency of drug administration while maintaining therapeutic immunosuppression, likely through combination or sustained-release formulation of established immunosuppressive agents.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:58:21.168Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Organ transplant rejection prevention"},{"name":"Autoimmune disease management"}]},"trialDetails":[{"nctId":"NCT01203722","phase":"PHASE1, PHASE2","title":"Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2010-09","conditions":"Hematologic Malignancies","enrollment":87},{"nctId":"NCT04738812","phase":"PHASE3","title":"Determination of Adequate Tuberculosis Regimen in Patients Hospitalized With HIV-associated Severe Immune Suppression","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2022-04-21","conditions":"Tuberculosis, HIV-1-infection, Immuno-Deficiency","enrollment":1330},{"nctId":"NCT01294020","phase":"PHASE2","title":"Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2011-05-25","conditions":"Intestine Transplantation, Kidney Transplantation, Lung Transplantation","enrollment":81},{"nctId":"NCT04773392","phase":"PHASE4","title":"Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2021-11-23","conditions":"Kidney Transplantation, Kidney Transplant Rejection","enrollment":20},{"nctId":"NCT06835322","phase":"PHASE2","title":"Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis","status":"RECRUITING","sponsor":"Alexandria University","startDate":"2025-02-20","conditions":"Glomerulonephritis","enrollment":100},{"nctId":"NCT03555448","phase":"PHASE4","title":"Once Daily Immunosuppression Regimen","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2018-06-04","conditions":"Kidney Transplant; Complications","enrollment":51},{"nctId":"NCT03577431","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at MGH","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-03-29","conditions":"Liver Transplant","enrollment":9},{"nctId":"NCT02118896","phase":"PHASE3","title":"Study to Ascertain if Prolonged Release Tacrolimus (FK506E - MR4) is Safe and Effective When Used in the Long Term and in Combination With Other Immunosuppressive Drugs in Patients Who Have Received a Transplant","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2003-02-24","conditions":"Heart Transplantation, Liver Transplantation, Kidney Transplantation","enrollment":850},{"nctId":"NCT01614665","phase":"PHASE2","title":"A Study to Compare How the Body Absorbs and Processes Two Different Formulations of the Anti-rejection Medication Tacrolimus (Advagraf® or Prograf®) in Children Receiving an Organ Transplant, and How Safe and Effective They Are Over a Longer Period of Time","status":"COMPLETED","sponsor":"Astellas Pharma Europe Ltd.","startDate":"2012-04-03","conditions":"Heart Transplantation, Kidney Transplantation, Liver Transplantation","enrollment":44},{"nctId":"NCT03654040","phase":"PHASE1, PHASE2","title":"Liver Transplantation With Tregs at UCSF","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-22","conditions":"Liver Transplant","enrollment":42},{"nctId":"NCT03797196","phase":"PHASE4","title":"RCT Comparing Immunosuppressive Regimens in Elderly Renal Transplant Recipients","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2019-07-29","conditions":"Renal Transplant Recipients, Elderly Patients, Immunosuppression","enrollment":374},{"nctId":"NCT03438773","phase":"PHASE1","title":"Prospective Pilot Feasibility Study Comparing Envarsus Once-a-day to Tacrolimus Twice-a-day Immunosuppressive Regimen on Drug Bioavailability in Hispanic First Time Kidney Transplant Recipients","status":"UNKNOWN","sponsor":"California Institute of Renal Research","startDate":"2018-07-11","conditions":"Kidney Transplant; Complications, Kidney Transplant Failure and Rejection","enrollment":50},{"nctId":"NCT04431219","phase":"PHASE1, PHASE2","title":"First in Human Study: LIS1, an Induction Treatment in Kidney Transplanted Patients","status":"COMPLETED","sponsor":"Xenothera SAS","startDate":"2019-11-26","conditions":"Kidney Transplant","enrollment":10},{"nctId":"NCT02088931","phase":"PHASE1","title":"Treg Adoptive Therapy for Subclinical Inflammation in Kidney Transplantation","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2014-03","conditions":"Late Complication From Kidney Transplant","enrollment":3},{"nctId":"NCT02137239","phase":"PHASE2","title":"Regimen Optimization Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12-31","conditions":"Kidney Transplantation","enrollment":58},{"nctId":"NCT01220856","phase":"PHASE2","title":"Reparixin in Pancreatic Islet Transplantation","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2010-07-28","conditions":"Pancreatic Islet Transplantation in Type 1 Diabetes Mellitus","enrollment":9},{"nctId":"NCT03339401","phase":"PHASE2","title":"The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2017-12-22","conditions":"Adenovirus","enrollment":29},{"nctId":"NCT02876679","phase":"PHASE2","title":"Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-04-06","conditions":"Graft vs Host Disease","enrollment":94},{"nctId":"NCT02188719","phase":"PHASE1","title":"Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12-17","conditions":"Liver Transplantation","enrollment":15},{"nctId":"NCT02954198","phase":"NA","title":"Once-daily Regimen With Envarsus® to Optimize Immunosuppression Management and Outcomes in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2016-12-01","conditions":"Immunosuppression","enrollment":40},{"nctId":"NCT02040584","phase":"PHASE3","title":"A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-20","conditions":"Liver Transplant","enrollment":217},{"nctId":"NCT02130817","phase":"PHASE4","title":"Belatacept in Kidney Transplantation of Moderately Sensitized Patients","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2014-09-24","conditions":"End Stage Renal Disease, Antibody Mediated Rejection","enrollment":""},{"nctId":"NCT02029638","phase":"PHASE2","title":"BMT and High Dose Post-Transplant Cyclophosphamide for Chimerism Induction and Renal Allograft Tolerance","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-01-07","conditions":"Kidney Transplantation","enrollment":4},{"nctId":"NCT03500848","phase":"PHASE2, PHASE3","title":"Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation","status":"UNKNOWN","sponsor":"Southern Medical University, China","startDate":"2018-05-01","conditions":"Liver Transplantation","enrollment":130},{"nctId":"NCT01328496","phase":"PHASE2","title":"Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2011-06-15","conditions":"Hematologic Malignancies, Disorder Related to Transplantation, Hematopoietic Malignancy","enrollment":14},{"nctId":"NCT00118352","phase":"PHASE2","title":"Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2005-03","conditions":"Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission","enrollment":12},{"nctId":"NCT00160966","phase":"PHASE4","title":"Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy","status":"COMPLETED","sponsor":"University of Giessen","startDate":"2004-09","conditions":"Polyomavirus Infections","enrollment":108},{"nctId":"NCT01023815","phase":"PHASE3","title":"Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-04","conditions":"de Novo Kidney Transplant Recipients, Renal Transplantation","enrollment":330},{"nctId":"NCT00418379","phase":"PHASE3","title":"Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets","status":"COMPLETED","sponsor":"Stallergenes Greer","startDate":"2006-12","conditions":"Allergy","enrollment":633},{"nctId":"NCT00189488","phase":"PHASE2","title":"Trial to Evaluate Palifermin in the Reduction of Acute Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Allogeneic Marrow/Peripheral Blood Progenitor Cell (PBPC) Transplantation","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-12","conditions":"Graft Versus Host Disease, Hematologic Malignancies","enrollment":155},{"nctId":"NCT00282256","phase":"PHASE2","title":"A Study of a Modified-Release Tacrolimus Based Immunosuppression Regimen in Stable Pediatric Liver Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2004-01","conditions":"Liver Transplantation","enrollment":19},{"nctId":"NCT00282243","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Liver Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2003-02","conditions":"Liver Transplantation","enrollment":70},{"nctId":"NCT00282568","phase":"PHASE2","title":"A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2002-08","conditions":"Kidney Transplantation","enrollment":70},{"nctId":"NCT01609673","phase":"NA","title":"Study of Everolimus in de Novo Renal Transplant Recipients","status":"TERMINATED","sponsor":"Helady Pinheiro, MD, PhD","startDate":"2013-03","conditions":"End Stage Renal Failure With Renal Transplant","enrollment":1},{"nctId":"NCT01154387","phase":"PHASE1, PHASE2","title":"Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection","status":"UNKNOWN","sponsor":"Tolera Therapeutics, Inc","startDate":"2010-07","conditions":"End Stage Renal Disease, Renal Transplant","enrollment":85},{"nctId":"NCT01875224","phase":"PHASE4","title":"Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression","status":"UNKNOWN","sponsor":"University of Arizona","startDate":"2013-08","conditions":"New Onset Diabetes After Transplant, Kidney Transplantation","enrollment":32},{"nctId":"NCT00587158","phase":"NA","title":"Oral Paricalcitol in Kidney Transplant Recipients","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2007-01","conditions":"Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary","enrollment":100},{"nctId":"NCT01213394","phase":"PHASE3","title":"Mycophenolate Mofetil for Reducing Cardiovascular Risk in Renal Transplant Recipients","status":"TERMINATED","sponsor":"Ramesh Prasad","startDate":"2010-10","conditions":"Kidney Transplantation, Cardiovascular Diseases","enrollment":2}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Once daily immunosuppression regimen","genericName":"Once daily immunosuppression regimen","companyName":"Washington University School of Medicine","companyId":"washington-university-school-of-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A once-daily immunosuppressive regimen that reduces immune system activity to prevent organ rejection or manage autoimmune conditions. Used for Organ transplant rejection prevention, Autoimmune disease management.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}